VitalCare Diabetes Treatment Centers, Inc. (Pink Sheets:VDTI), a Nevada corporation, today announced they have signed a letter of intent to open two new Diabetes Treatment and Wound Care Centers in Indiana. The centers will be administering the FDA approved iCAT treatment for diabetes and related wound care for Type 1 and Type 2 diabetes patients. These are the first of a series of centers to be opened in the Midwest of the United States.
CARSON CITY, Nev. (Business Wire EON) April 29, 2008 --
VitalCare Diabetes Treatment Centers, Inc. (Pink Sheets:VDTI), a Nevada
corporation, today announced they have signed a letter of intent to open
two new Diabetes Treatment and Wound Care Centers in Indiana. The
centers will be administering the FDA approved iCAT treatment for
diabetes and related wound care for Type 1 and Type 2 diabetes patients.
These are the first of a series of centers to be opened in the Midwest
of the United States.
Jimmy McDougald, CEO of VitalCare, stated, “This
is the beginning of our Midwest launch and we are excited to be offering
iCAT therapy to diabetics in this region.”
Tristan V. Voth-Stonger, MD, Executive Vice President & CMO of
VitalCare, has identified the centers (Peru, IN and Indianapolis, IN)
and structured the LOI, and stated, “These
facilities were handpicked for their strategic locations and capacity
for growth.”
About VitalCare Diabetes Treatment Centers, Inc.
VitalCare Diabetes Treatment Centers, Inc. is a company specializing in
providing Administrative, Marketing, Business Development, Strategic
Planning, Clinical Oversight and Clinical Management Services to the
Diabetes Healthcare Sector, with an emphasis in bringing "Cutting Edge"
medical devices and healthcare services direct to consumers, focusing on
an emerging FDA approved, US and European Patented technology and
treatment intervention for treating Type 1 and Type 2 Diabetes known as “Intracellular
Activation Therapy (iCAT).”
Safe Harbor Statement: Forward-looking statements in this release with
respect to VitalCare Diabetes Treatment Centers, Inc.’s
business, financial condition and results of operations, as well as
matters of timing and the prospective terms of the transaction described
are subject to risks and uncertainties that could cause actual results
to differ materially from those expressed in the forward-looking
statements, including, but not limited to, certain delays beyond
VitalCare Diabetes Treatment Centers, Inc.’s
control with respect to market acceptance of their technology and/or
products, whether financing will be available, the effect of the
application of acquisition accounting policies as well as certain other
risk factors which are and may be detailed from time to time in VitalCare’s
filings with the Securities and Exchange Commission.
Trackback URL: http://www.prweb.com/pingpr.php/SW5zZS1TaW5nLUNvdXAtU3VtbS1GYWx1LVplcm8=
|
